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Summary Background: Chronic obstructive pulmonary disease (COPD) is charac-
terised by chronic inflammation of the respiratory tract.
Methods: We investigated the presence of interleukin-6 (IL-6: a cytokine secreted
by monocytes/macrophages, T cells, B cells, fibroblasts, bone marrow stromal cells,
keratinocytes and endothelial cells) in the exhaled breath condensate of 16 ex-
smokers with moderate COPD, 12 healthy non-smokers. IL-6 was measured by means
of a specific enzyme immunoassay.
Results: IL-6 levels were detectable in all of the subjects, but were higher in the
COPD patients (8.070.1 pg/ml; Po0:0001) than in the healthy non-smokers
(4.970.2 pg/ml) with a correlation in this group between age and IL-6 levels
(r ¼ 0:597; Po0:05).
Conclusions: The increased IL-6 levels in exhaled breath condensate may reflect
airway inflammation in patients with COPD.
& 2003 Elsevier Ltd. All rights reserved.
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Introduction
Chronic obstructive pulmonary disease (COPD) is
characterised by the presence of airflow obstruc-
tion due to chronic bronchitis or emphysema, which
usually occur together,1 and causes the progressive
destruction of the alveolar walls.
Previous studies have shown that increased
interleukin-6 (IL-6) levels and inflammation may
be associated with the progression of COPD.2 IL-6 is
produced in the lung by interstitial fibroblasts,
alveolar macrophages, and large-vessel and bron-
chial epithelial cells. IL-6 levels are high in chronic
inflammatory conditions of the lung, such as those
due to allogeneic transplantation, bleomycin-in-
duced fibrosis and a variety of human interstitial
lung diseases.3 High levels of IL-6 have been found
in the induced sputum of patients with COPD,
particularly during exacerbation.4
Exhaled condensate may contain molecules
coming from the mouth, tracheobronchial system
and alveoli, but their proportional contribution is
still unclear. It is assumed that airway surface liquid
becomes aerosolised during turbulent airflow and
that the content of the condensate reflects the
composition of airway surface liquid, although
large molecules may not aerosolise as efficiently
as small and soluble ones.5
A strong correlation between the levels of CO2
and O2 in exhaled fluid and exhaled breath suggests
that aerosol particles exhaled in human breath
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reflect the composition of the bronchoalveolar
extracellular lining fluid.6
The aim of this study was to investigate whether
IL-6 can be detected in the breath condensate of
COPD patients and to compare its concentration
with that in healthy subjects.
Materials and methods
The study involved 16 patients with moderate
COPD, and 12 age-matched healthy controls. COPD
was diagnosed according to the Guidelines of the
British Thoracic Society.8 All of the patients had
been clinically stable for a least 8 weeks. They
were all ex-smokers who had given up at least 6
months before the study.
The control subjects had no pulmonary disorders
and had shown no signs of upper or lower
respiratory tract infection during the previous 8
weeks. All were lifelong non-smokers (Table 1).
Exhaled breath condensate
The breath condensate samples were collected
using a specially designed condensing chamber
(Ecoscreen; Jaeger, Hoechberg, Germany) as pre-
viously described.9
IL-6 assay
IL-6 concentrations in the breath condensate were
measured using a specific enzyme immunoassay kit
(EIA) (Cayman Chemical, Ann Arbor, USA). The
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Table 1 Physical characteristics and pulmonary function of control subjects and COPD patients.
Control subjects Sex Age(yr.) Medicationn FEV1 l (% pred.
w)
M 70 No 3.18(89)
M 75 No 2.96(98)
F 57 No 2.09(101)
F 60 No 2.02(86)
M 42 No 4.56(90)
F 55 No 2.57(91)
M 54 No 2.53(98)
M 52 No 2.37(88)
F 75 No 2.87(88)
F 47 No 2.97(108)
M 45 No 3.96(100)
M 52 No 2.5(83)
Mean7SD 57.3711.1 2.970.7 (93.377.5)
COPD subjects
M 52 A 1.5(41)
F 68 B 1.36(48)
M 70 A 1.23(49)
M 53 A 1.4(35)
M 65 A 1.47(44)
M 72 A 1.35(47)
M 54 A 1.2(35)
F 60 A 0.88(38)
M 74 A 0.9(39)
M 70 A 1.3(47)
M 68 A 0.9(35)
F 57 B 1.1(45)
M 75 A 1.05(35)
F 49 A 1.27(43)
M 75 A 1.05(36)
F 60 A 0.95(40)
Mean7SD 63.978.9 1.270.2(41.175.1)
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; data are expressed as mean values7SD.
nA, inhaled B2 sympathomimetic agent; B, inhaled anticholinergic agent.
w% predicted of European Respiratory Society [7].
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assay was directly validated by means of gas
chromatography/mass spectrometry. The intra-as-
say and inter-assay variability were 10% or less. The
detection limit of the assay was 1.5 pg/ml after a 2-
h development period. The reproducibility of
repeat IL-6 measurements was assessed by the
Bland and Altman method and the coefficient of
variation.10
Statistical analysis
Unpaired t-test were used to compare the two
groups, and correlations between variables were
performed using Spearman’s rank correlation test,
Po0:05 being considered significant.
Results
IL-6 was detectable in the breath condensate of all
the healthy non-smokers (4.970.1 pg/ml), but was
significantly higher in the COPD patients
(8.070.2 pg/ml; Po0:0001) (Fig. 1).
IL-6 levels tended to increase with age in the
control group (r ¼ 0:597; Po0:05) but not in the
COPD group. No correlation could be found be-
tween IL-6 and lung function in either group.
Discussion
This is the first study to examine IL-6 levels, in the
exhaled breath condensate of patients with COPD,
which were found to be higher than those of the
healthy controls.
Increased serum IL-6 levels have been reported in
patients with interstitial lung disease and pleural
effusion, collagen-vascular disease, inflammatory
bowel disease, infectious diseases, and benign or
malignant hematological diseases, and it has been
suggested that circulating and local levels of IL-6
may reflect disease activity and be useful in
evaluating prognosis.11
Park et al. found increased IL-6 levels in the BAL
fluid of patients with non-specific interstitial
pneumonia/fibrosis and in some patients with
interstitial pneumonia.3 Dowlati et al. have re-
ported increased levels of IL-6 in the serum and BAL
fluid of patients with lung cancer.12 A recent study
by Bhowmik et al.4 found increased IL-6 and IL-8
levels in the sputum of COPD patients with frequent
exacerbations.
These studies show that inflammatory markers
can be detected in the respiratory tract using
invasive techniques such as bronchoaleolar lavage
or less invasive techniques such as induced sputum.
However, these procedures cannot be repeated
within a short period of time because they may
induce an inflammatory response themselves and
are relatively unacceptable for the patients.
Exhaled breath condensate is totally non-invasive
and highly acceptable to patients. The collection
procedure has no effect on airway function or
inflammation, and there is growing evidence that
abnormalities in condensate composition may
reflect biochemical changes in airway lining fluid.5
This method has been successfully used in previous
studies to investigate several inflammatory markers
in COPD and asthma patients such as hydrogen
peroxide,9 isoprostanes,13 and prostanoids.
The measurement of IL-6 in exhaled air can
therefore provide a useful, sensitive, and non-
invasive means of studying inflammatory markers.
The small increase of IL-6 levels with age in healthy
subjects need to be corroborated by studies in a
larger population.
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Figure 1 Exhaled breath condensate levels of IL-6 in
COPD patients and healthy subjects.
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